Movement Alert｜SKB BIO Intraday Rise 3.72% in Regular Trading, Innovative Drug Sentiment Lifted by Strong China Out-licensing Data

Market Focus10-21

On October 21, SKB BIO recorded an Intraday Rise of 3.72% in Regular Trading, trading at HK$488.4, with turnover of HK$20.23 million.

The clearest recent catalyst is sector-wide strength in innovative drug names after officials said China innovative drug outbound licensing reached about $130 billion in the first three quarters, close to the full-year level of last year. In that sector move, multiple Hong Kong-listed biotech and pharma stocks advanced, including Hansoh Pharma, WuXi Biologics, Kelun-Biotech and others.

Supporting company-specific context has also been constructive. SKB BIO reported first-half revenue of RMB978 million, up 2.9%, while adjusted net profit turned positive at RMB479 million from a loss a year earlier, helped by rapid growth in commercialized innovative drugs. In addition, its partner previously reported positive mid-stage data for SKB378/WIN378 in asthma and started phase 3 development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment